drug · small molecule
pelabresib
Phase 3updated 3mo agoby $NVS NOVARTIS AG🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and 9 investigational indications.
targets
Bromodomain and extra-terminal motif (BET)
all catalysts(0)
nothing on the calendar yet
Trials studying pelabresib
- phase3A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- phase1Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
- phase1Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
- phase1A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
- phase3Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
- phase2A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
- phase1Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
- phase3An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 13m ago
Found something off?
comments(0)
5-min edit window · permanent after that